Value through Innovation30 July 2014

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive

16.12.2013

Hepatitis C: Phase III data show Boehringer Ingelheim’s faldaprevir* is effective even in patients with common drug-resistant viral variant

- For media outside of the US, the UK & Canada only
10.12.2013

New data analyses show consistent efficacy and safety profile of Pradaxa® in broad range of patients with acute deep vein thrombosis or pulmonary embolism*

- For media outside of the US, the UK & Canada only
03.12.2013

New study showed significant reduction in blood glucose with Linagliptin alone and in combination with metformin in adults newly diagnosed with Type 2 Diabetes

- For Non-US and Non-UK Media
02.12.2013

Largest global survey investigating early Type 2 Diabetes conversations launched by Boehringer Ingelheim and Eli Lilly and Company in partnership with the International Diabetes Federation

- For Non-US and Non-UK Media
26.11.2013

Hepatitis C: Boehringer Ingelheim’s faldaprevir granted accelerated assessment from European Medicines Agency

- For media outside of the U.S.A., UK and Canada only
25.11.2013

Pradaxa® (dabigatran etexilate) 150mg bid continues to be the only oral anticoagulant which showed superior ischaemic stroke reduction vs. warfarin in its pivotal study RE-LY® – Results of the ENGAGE AF-TIMI 48 trial published for edoxaban vs. warfarin do not change the position of Pradaxa®

- For media outside of the US, the UK & Canada only
19.11.2013

New long-term treatment data confirms consistent benefit and safety profile of Pradaxa® beyond 6 years

- For media outside of the US, the UK & Canada only
19.11.2013

Boehringer Ingelheim planning two new Global Clinical Trials for Pradaxa® (dabigatran etexilate) in expanded patient populations

- For media outside of the US, the UK & Canada only
18.11.2013

First human data show promise of Boehringer Ingelheim's specific antidote for immediate, complete and sustained reversal of Pradaxa®-induced anticoagulation

- For media outside of the US, the UK & Canada only
15.11.2013

Boehringer Ingelheim goes "Blue" in supporting World Diabetes Day activities

13.11.2013

Boehringer Ingelheim submits applications in Europe to extend the indication for the use of tiotropium Respimat® to the treatment of asthma in adults aged 18 years and over

- For Media outside the U.S., Canada and UK
12.11.2013

Boehringer Ingelheim supports victims of typhoon Haiyan in the Philippines


12.11.2013

New efficacy and safety data for Pradaxa® (dabigatran etexilate) to be announced at American Heart Association's Scientific Sessions 2013

- For media outside of the US, the UK & Canada only
11.11.2013

Micardis crosses 50 million patient-years of experience on 15th anniversary

- For NON-US and NON-UK Healthcare Media Only
07.11.2013

New data presented at AASD further demonstrate benefits of Trajenta® (linagliptin) with efficacy and safety in specific patient populations

- For Non-US and Non-UK Media
06.11.2013

New survey in four major Asian countries reveals complexity of managing Type 2 Diabetes is currently underestimated1

- Ex-US & Ex- UK Medical Media Only
02.11.2013

Phase III data show Boehringer Ingelheim's faldaprevir* was highly effective in a broad range of patients with genotype-1 hepatitis C

- For media outside of the U.S.A., UK and Canada only
02.11.2013

Boehringer Ingelheim's interferon-free hepatitis C treatment portfolio strengthened by promising Phase II data

- For media outside of the U.S.A., UK and Canada only